Influenza Virus Vaccines: Lessons from the 2009 H1N1 pandemic
Identifieur interne : 000C45 ( Main/Exploration ); précédent : 000C44; suivant : 000C46Influenza Virus Vaccines: Lessons from the 2009 H1N1 pandemic
Auteurs : Andrew J. Broadbent [États-Unis] ; Kanta Subbarao [États-Unis]Source :
- Current opinion in virology [ 1879-6257 ] ; 2011.
Abstract
Reflecting on the 2009 H1N1 pandemic, we summarize lessons regarding influenza vaccines that can be applied in the future. The two major challenges to vaccination during the 2009 H1N1 pandemic were timing and availability of vaccine. Vaccines were, however, well-tolerated and immunogenic, with inactivated vaccines containing 15μg of HA generally inducing antibody titers ≥1:40 in adults within 2 weeks of the administration of a single dose. Moreover, the use of oil-in-water adjuvants in Europe permitted dose- reduction, with vaccines containing as little as 3.75 or 7.5μg HA being immunogenic. Case-control studies demonstrated that monovalent 2009 H1N1 vaccines were effective in preventing infection with the 2009 H1N1 virus, but preliminary data suggests that it is important for individuals to be re-immunized annually.
Url:
DOI: 10.1016/j.coviro.2011.08.002
PubMed: 22125588
PubMed Central: 3224079
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000580
- to stream Pmc, to step Curation: 000580
- to stream Pmc, to step Checkpoint: 000813
- to stream Ncbi, to step Merge: 000714
- to stream Ncbi, to step Curation: 000714
- to stream Ncbi, to step Checkpoint: 000714
- to stream Main, to step Merge: 000C49
- to stream Main, to step Curation: 000C45
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influenza Virus Vaccines: Lessons from the 2009 H1N1 pandemic</title><author><name sortKey="Broadbent, Andrew J" sort="Broadbent, Andrew J" uniqKey="Broadbent A" first="Andrew J." last="Broadbent">Andrew J. Broadbent</name><affiliation wicri:level="2"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation wicri:level="2"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22125588</idno><idno type="pmc">3224079</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224079</idno><idno type="RBID">PMC:3224079</idno><idno type="doi">10.1016/j.coviro.2011.08.002</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">000580</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000580</idno><idno type="wicri:Area/Pmc/Curation">000580</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000580</idno><idno type="wicri:Area/Pmc/Checkpoint">000813</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000813</idno><idno type="wicri:Area/Ncbi/Merge">000714</idno><idno type="wicri:Area/Ncbi/Curation">000714</idno><idno type="wicri:Area/Ncbi/Checkpoint">000714</idno><idno type="wicri:doubleKey">1879-6257:2011:Broadbent A:influenza:virus:vaccines</idno><idno type="wicri:Area/Main/Merge">000C49</idno><idno type="wicri:Area/Main/Curation">000C45</idno><idno type="wicri:Area/Main/Exploration">000C45</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Influenza Virus Vaccines: Lessons from the 2009 H1N1 pandemic</title><author><name sortKey="Broadbent, Andrew J" sort="Broadbent, Andrew J" uniqKey="Broadbent A" first="Andrew J." last="Broadbent">Andrew J. Broadbent</name><affiliation wicri:level="2"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation wicri:level="2"><nlm:aff id="A1">Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><series><title level="j">Current opinion in virology</title><idno type="ISSN">1879-6257</idno><idno type="eISSN">1879-6265</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P2">Reflecting on the 2009 H1N1 pandemic, we summarize lessons regarding influenza vaccines that can be applied in the future. The two major challenges to vaccination during the 2009 H1N1 pandemic were timing and availability of vaccine. Vaccines were, however, well-tolerated and immunogenic, with inactivated vaccines containing 15μg of HA generally inducing antibody titers ≥1:40 in adults within 2 weeks of the administration of a single dose. Moreover, the use of oil-in-water adjuvants in Europe permitted dose- reduction, with vaccines containing as little as 3.75 or 7.5μg HA being immunogenic. Case-control studies demonstrated that monovalent 2009 H1N1 vaccines were effective in preventing infection with the 2009 H1N1 virus, but preliminary data suggests that it is important for individuals to be re-immunized annually.</p></div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Broadbent, Andrew J" sort="Broadbent, Andrew J" uniqKey="Broadbent A" first="Andrew J." last="Broadbent">Andrew J. Broadbent</name></region><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:3224079
|texte= Influenza Virus Vaccines: Lessons from the 2009 H1N1 pandemic
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22125588" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |